BAM
ABCL icon

Blueshift Asset Management’s AbCellera Biologics ABCL Stock Holding History

Blueshift Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-32,574
Closed -$318K – 644
2022
Q1 		$318K Buy
+32,574
New +$308K 0.03% 590

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Blueshift Asset Management's ABCL Position: Q2 2022 in Review

Blueshift Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 32,574 shares — an estimated $318K sold.

Blueshift Asset Management first reported a position in ABCL in Q1 2022 and held it in 1 quarter. The position peaked at $318K in Q1 2022. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

  • Blueshift Asset Management reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 32,574 AbCellera Biologics shares in Q2 2022, an estimated $318K.
  • Blueshift Asset Management first reported a position in AbCellera Biologics in Q1 2022 and held it in 1 quarter.
  • Blueshift Asset Management's AbCellera Biologics position peaked at $318K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.